Abstract:1667 Substitutions and deletions in exons in the tyrosine kinase domain of the EGFR gene (exons 18 to 24) in lung tumors have been associated with sensitivity to molecular target therapeutic agents classified as tyrosine kinase inhibitors (TKIs). Among the TKIs are gefitinib and erlotinib, which produce objective responses in 10-20% of advanced NSCLC patients after chemotherapy. Erlotinib prolongs survival in these patients. The relationship between mutation and response and survival is imperfect, suggesting that other factors may play a role in determining sensitivity to TKIs. Recently we found EGFR amplification to be frequent in NSCLC (13%) and to be related to gefitinib response and survival. In this report, we examined genomic DNAs from 78 NSCLC and 20 SCLC lung cancer cell lines. Exons 18-21 of the tyrosine kinase domain were amplified and sequenced for the presence of mutations. Mutations were found in none of the SCLC lines and 8 of 78 NSCLC lines (10%), namely NCI-H820, NCI-H1650, NCI-H1975, NCI-H3255, HCC827, HCC2279, HCC2935 and HCC4006. These cell lines were initiated from 7 Caucasian patients and one of Oriental origin. Most patients were light or never smokers. Six of the mutations were deletions in exon 19 and two were the L858R point mutation in exon 21. Dual color fluorescence in situ hybridization analysis was performed in 35 NSCLC lines using the EGFR/CEP 7 probe (Vysis/Abbott). EGFR gene amplification was identified in 7 of these lines, all carrying EGFR mutations. H3255, HCC827, HCC2259, and HCC4006 had large, clustered gene amplification in all cells; H1650 had focal gene amplification with large gene clusters in approximately 30% of cells; NCI-H820 and HCC2935 showed small gene clusters in interphase nuclei and apparently normal metaphase chromosomes, supporting the hypothesis that rearranged chromosomes harbor gene duplications. The remaining mutated line, NCI-1975 had no evidence of amplification. Chromosomes harboring large amplicons including EGFR were distinct among the lines. H3255 showed gene clusters in two distinct chromosomes, a large der(7) with three layers of gene clusters and a large metacentric with numerous layers of gene clusters in both arms. HCC827, HCC4006 and H1650 carried the EGFR amplification in the long arm of der(7) with large gene clusters interspaced by centromeric sequences. Preliminary in vitro testing showed that the majority of the mutated lines were sensitive to gefitinib and that there was a correlation between gefitinib sensitivity and the degree of gene amplification. These results identified gene amplification as frequently associated with mutations in the tyrosine kinase domain of the EGFR gene in NSCLC cell lines and support the role of both amplification and mutation in the sensitivity to TKIs.

What do we know about the molecular and biological features of EGFR in glioblastomas and non-small cell lung cancer?

Pathological Significance of Epidermal Growth Factor Receptor Expression and Amplification in Human Gliomas

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas.

Epidermal growth factor receptor mutations in lung cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Next Generation Sequencing and Molecular Imaging Identify EGFR Mutation and Amplification in a Glioblastoma Multiforme Patient Treated with an EGFR Inhibitor: a Case Report.

Abstract LB-518: Amplification and Activation of EGFR Wild-Type Mediates Invasion of Human Glioblastoma in Vivo

Structural alterations of the EGFR gene in glioblastoma samples as a prognostic factor and molecular target for therapy

An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma

Comprehensive Analysis Reveals Epithelial Growth Factor Receptor as a Potential Diagnostic Biomarker in Glioblastoma Multiforme

EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review

Updated Insights on EGFR Signaling Pathways in Glioma

The analysis of EGFR variants in Chinese adult glioblastoma patients.

EGFR Mutation Promotes Glioblastoma Through Epigenome and Transcription Factor Network Remodeling

Current Status and Future Possibilities

Gefitinib sensitivity in non-small cell lung cancer (NSCLC) cell lines associates with mutation and amplification of the epidermal growth factor receptor (EGFR) gene

Somatic Mutations of the Epidermal Growth Factor Receptor and Non-Small-cell Lung Cancer

Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics

EGFR Exon20 Insertion Mutations in Non-Small Cell Lung Cancer: Clinical Implications and Recent Advances in Targeted Therapies.

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer